SpotitEarly Raises $20.3M to Revolutionize Cancer Pre-Screening with AI-Driven Breath Test Innovation

SpotitEarly is excited to announce the successful raising of $20,300,000 in our latest funding round, a milestone that marks a transformative moment in our journey to revolutionize cancer pre-screening. As an innovator in the realm of early cancer detection, SpotitEarly leverages a cutting-edge, AI-based test capable of detecting multiple cancer types from a single breath sample. This breakthrough technology harnesses the science of scent to identify cancerous volatile organic compounds (VOCs) in exhaled breath, offering a highly efficient, non-invasive, and reliable diagnostic tool. With an impressive 94% accuracy in both sensitivity and specificity, our solution is designed for early-stage detection, significantly widening the window for treatment options and improvement in survival rates. The new capital infusion will accelerate our mission to make pre-screening accessible and affordable for everyone. We plan to enhance our research and development capabilities, further refine our AI algorithms, and scale production of our off-the-shelf test kits to meet growing global demand. By eliminating traditional barriers and enabling easy, at-home sample collection without the need for healthcare professional assistance, we are confident that our solution will empower individuals and healthcare systems alike, particularly in underserved communities. The future holds a promise where cancer prevention is not just an option for the few, but a universally accessible service that saves lives and brings peace of mind. As we continue to innovate and expand our reach, we invite partners, investors, and the global community to join us in transforming cancer diagnostics and elevating the quality of life for millions around the world.